The Minister for Health Stephen Donnelly TD has published a Report prepared by Mazars which examines the governance arrangements around the HSE’s drug reimbursement process.
The Report found that the HSE process is operating in line with the legislation and that it is delivering results in keeping with international norms. The Report concluded that there is scope for improvements in a number of areas, including:
Minister Donnelly said; “I want to see improvements in the overall transparency of the process, and I have asked the HSE to bring forward proposals in that regard as a matter of urgency. Greater engagement with stakeholders, including patient groups, will ensure that patients are aware of the process and have sight of various steps and timelines”.
In that respect the Minister has asked the HSE to introduce an application tracker on the HSE’s website, detailing how applications progress through the process. He has also asked the HSE to introduce indicative timelines for a medicine to complete the application/approval process. That work is now progressing.
An Implementation Plan is being published and an Implementation Working Group is being established between the Department of Health and the HSE. This Group will consider and progress the various recommendations contained in the Report as well as other options to improve the process.
The Working Group will have regard to the policy, legal and institutional framework within which the HSE operates, in particular the requirements set out in the Health (Pricing and Supply of Medical Goods) Act 2013, the Health Act 2004 and the existing processes described in Framework Agreements with industry on the supply and pricing of medicines. The Group will engage with all stakeholders, including patient groups and industry, in seeking to bring about further improvements to the reimbursement process. The Working Group is due to report to the Minister in six months.
Highlighted Articles
